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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 90, Revision 1 
(FGE.90Rev1): consideration of six substances evaluated by JECFA (68th 
meeting) structurally related to aliphatic, alicyclic and aromatic saturated 
and unsaturated tertiary alcohols, aromatic tertiary alcohols and their 
esters evaluated by EFSA in FGE.18Rev1 and FGE.75Rev11 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of EFSA was requested to 
consider evaluations of flavouring substances assessed since 2000 by the Joint FAO/WHO Expert Committee on 
Food Additives (the JECFA), and to decide whether further evaluation is necessary, as laid down in Commission 
Regulation (EC) No 1565/2000. The present consideration concerns a group of six aliphatic, acyclic and 
alicyclic terpenoid tertiary alcohols and structurally related substances evaluated by JECFA at the 68th meeting 
in 2007. This revision of FGE.90 is made because additional toxicity data have become available for a 
structurally related substance in FGE.75Rev1, anhydrolinalool oxide (5) [FL-no: 13.097]. The Panel agrees with 
the application of the Procedure as performed by the JECFA for four substances [FL-no: 02.018, 02.245, 02.250 
and 02.251]. For two substances [FL-no: 13.076 and 13.087] it could not be concluded that they are metabolised 
to innocuous substances. Based on the exposure estimates (MSDI) and the no observed adverse effect level 
(NOAEL) from 90-day toxicity study with anhydrolinalool oxide (5), the Panel considered that the substances 
[FL-no: 13.076 and 13.087] were not of safety concern at the estimated levels of intake based on the maximised 
survey-derived daily intake (MSDI) approach. The specifications for the materials of commerce have also been 
considered. For substance [FL-no: 02.251] information on the stereoisomeric composition has not been 
specified, and for substance [FL-no: 13.087], the identity of the isomers needs to be specified. For three 
substances [FL-no: 02.018, 13.076 and 13.087] the modified theoretical added maximum daily intake 
(mTAMDI) is above the threshold of concern and therefore more reliable exposure data are required to perform 
a more refined exposure estimation and to judge whether a re-evaluation according to the Procedure is needed. 
                                                     
 
1  On request from the European Commission, Question Nos EFSA-Q-2013-00195 and EFSA-Q-2013-00196, adopted on 
2 December 2015. 
2  Panel members: Claudia Bolognesi, Laurence Castle, Jean-Pierre Cravedi, Karl-Heinz Engel, Paul Fowler, Roland Franz, 
Konrad Grob, Rainer Gürtler, Trine Husøy, Wim Mennes, Maria Rosaria Milana, André Penninks, Maria de Fatima 
Tavares Poças, Vittorio Silano, Andrew Smith, Christina Tlustos, Fidel Toldra, Detlef Wölfle and Holger Zorn. 
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SUMMARY 
Following a request from the European Commission, the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientific opinion to provide 
scientific advice to the Commission on the implications for human health of chemically defined 
flavouring substances used in or on foodstuffs in the Member States. In particular, the Panel was 
requested to consider the Joint FAO/WHO Expert Committee on Food Additives (the JECFA) 
evaluations of flavouring substances assessed since 2000, and to decide whether no further evaluation 
is necessary, as laid down in Commission Regulation (EC) No 1565/2000. These flavouring 
substances are listed in the Register, which was adopted by Commission Decision 1999/217/EC and 
its consecutive amendments. 
In Flavouring Group Evaluation 90 (FGE.90), the European Food Safety Authority (EFSA) considered 
six flavouring substances from a group of flavouring substances consisting of acyclic and alicyclic 
terpenoid tertiary alcohols and structurally related substances evaluated by JECFA at the 68th meeting. 
The JECFA has evaluated a group of 15 flavouring substances consisting of aliphatic, acyclic and 
alicyclic terpenoid tertiary alcohols, and structurally related substances. Two of the JECFA evaluated 
substances are not in the Register ((±)-ethyl 2-hydroxy-2-methylbutyrate, JECFA no: 1651 and (±)-
ethyl 2-hydroxy-3-methylbutyrate, JECFA no: 1652). Seven tertiary alcohols [FL-no: 02.035, 02.037, 
02.042, 09.086, 09.227, 09.232 and 09.509] have been considered in FGE.89. Therefore, this 
consideration only deals with six substances. 
This revision of FGE.90 is made because EFSA received new toxicity data on anhydrolinalool oxide 
[FL-no: 13.097] from FGE.75 which support the evaluation of [FL-no: 13.076 and 13.087] in this 
FGE. 
The Panel concluded that the six substances [FL-no: 02.018, 02.245, 02.250, 02.251, 13.076 and 
13.087] are structurally related to the aliphatic, alicyclic and aromatic saturated and unsaturated 
tertiary alcohols, aromatic tertiary alcohols and their esters evaluated by EFSA in the Flavouring 
Group Evaluation 18, Revision 3 (FGE.18Rev3). 
The Panel agrees with the way the application of the Procedure has been performed by the JECFA for 
four of the six substances [FL-no: 02.018, 02.245, 02.250 and 02.251]. For the remaining two 
substances [FL-no: 13.076 and 13.087], no metabolism data are available, neither for the substances 
themselves nor for related substances. Therefore, in contrast to the JECFA, the Panel cannot conclude 
that these substances are metabolised to innocuous products and they should accordingly be evaluated 
via the B-side of the Procedure scheme. The present revision of FGE.90, FGE.90Rev1, includes the 
consideration of new available toxicity data made available since the publication of FGE.90. A no 
observed adverse effect level (NOAEL) of 52 mg/kg body weight (bw) was derived from a 90-day 
study in rats for the structurally related substance anhydrolinalool oxide. Compared with an exposure 
estimate of 0.12 µg /capita per day for both [FL-no: 13.076 and 13.087], a margin of safety of 26 × 
106 can be calculated.  
Thus for four substances [FL-no: 02.018, 02.245, 02.250 and 13.076], the Panel agrees with the 
JECFA conclusion ‘no safety concern at estimated level of intake as flavouring substances’ based on 
the MSDI approach. 
For the six substances, use levels have been provided by the Industry [FL-no: 02.018, 02.245, 02.250, 
02.251, 13.076 and 13.087]. The modified theoretical added maximum daily intake (mTAMDI) 
figures calculated for three of the six substances [FL-no: 02.018, 13.076 and 13.087] are above the 
threshold of concern for their structural classes. For these substances, more reliable exposure data are 
needed. On the basis of such data, the substances should be reconsidered using the Procedure. 
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Adequate specifications are available for four out of six materials of commerce. For substance [FL-no: 
02.251] information on the stereoisomeric composition and for substance [FL-no: 13.087] the identity 
of the isomers and the stereoisomeric composition needs to be specified. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavourings is regulated under Regulation (EC) No 1334/2008 of the European Parliament 
and the Council of 16 December 2008 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and 
approval are required for flavouring substances. 
The Union list of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/2012. The list contains flavourings substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000. 
The European Food Safety Authority (EFSA) has considered the Joint FAO/WHO Expert Committee 
on Food Additives (the JECFA) evaluation of 11 tetrahydrofuran and furanone derivatives in the 
flavouring group evaluation 75 (FGE.75). The opinion was adopted on 1 April 2008. 
EFSA concluded in its opinion that for anhydrolinalool oxide (5) [FL-no 13.097] it did not find that it 
could be metabolised to innocuous products and should accordingly be evaluated via the B-side of the 
Procedure scheme. A no observed adverse effect level (NOAEL) could not be identified for the 
substance itself or for structurally related substances and accordingly, additional data are required for 
this substance. 
EFSA has considered the JECFA evaluation of 15 flavouring substances consisting of aliphatic, 
acyclic and alicyclic terpenoid tertiary alcohols and structurally related substances in the flavouring 
group evaluation 90 (FGE.90). The opinion was adopted in 24 September 2009. 
EFSA concluded in its opinion that for the 6-hydroxydihydrotheaspirane [FL-no 13.076] and 6-
acetoxydihydrotheaspirane [FL-no 13.087] no metabolism data are available, neither for the 
substances themselves nor for the related substances. Therefore, in contrast to the JECFA, EFSA 
cannot conclude that these substances are metabolised to innocuous products and they should 
accordingly be evaluated via the B-side of the Procedure scheme. NOAEL could not be identified for 
these two substances or for structurally related substances and accordingly, additional data are 
required. 
The requested information on one representative material, anhydrolinalool oxide (5) [FL-no 13.097] 
has now been submitted by the European Flavour Association. This information is intended to cover 
the re-evaluation of this substance and of the two substances, 6-hydroxydihydrotheaspirane [FL-no 
13.076] and 6-acetoxydihydrotheaspirane [FL-no 13.087]. 
The Commission asks EFSA to evaluate this new information and depending on the outcome proceed 
to the full evaluation of the flavouring substances. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requested ESFA to carry out a safety assessment on the following three 
flavouring substances: anhydrolinalool oxide (5) [FL-no 13.097], 6-hydroxydihydrotheaspirane [FL-
no: 13.076] and 6-acetoxydihydrotheaspirane [FL-no: 13.087] in accordance with Commission 
Regulation (EC) No 1565/2000.   
INTERPRETATION OF THE TERMS OF REFERENCE 
The present scientific opinion FGE.90 Revision 1 covers the safety assessment of the following 
flavouring substances: 6-hydroxydihydrotheaspirane with [FL 13.076] and 6-
acetoxydihydrotheaspirane [FL 13.087]. 
Flavouring Group Evaluation 90, Revision 1
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ASSESSMENT 
The approach used by EFSA for safety evaluation of flavouring substances is referred to in 
Commission Regulation (EC) No 1565/2000, hereafter named the ‘EFSA Procedure’. This Procedure 
is based on the opinion of the Scientific Committee on Food (SCF, 1999), which has been derived 
from the evaluation procedure developed by the JECFA (JECFA, 1995; JECFA, 1996; JECFA, 1997; 
JECFA, 1999), hereafter named the ‘JECFA Procedure’. The Panel on Food Contact Materials, 
Enzymes, Flavourings and Processing Aids (the Panel) compares the JECFA evaluation of structurally 
related substances with the result of a corresponding EFSA evaluation, focussing on specifications, 
intake estimations and toxicity data, especially genotoxicity data. The evaluations by EFSA will 
conclude whether the flavouring substances are of no safety concern at their estimated levels of intake, 
whether additional data are required or whether certain substances should not be evaluated through the 
EFSA Procedure. 
The following issues are of special importance. 
Intake 
In its evaluation, the Panel as a default uses the maximised survey-derived daily intake (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe.  
In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both 
European and USA production figures. The higher of the two MSDI figures is used in the evaluation 
by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, 
meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of 
these figures. For Register substances for which this is the case, the Panel will need EU production 
figures in order to finalise the evaluation. 
When the Panel examined the information provided by the European Flavour Industry on the use 
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would 
grossly underestimate the intake by regular consumers of products flavoured at the use level reported 
by the Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65th meeting 
considered ‘how to improve the identification and assessment of flavouring agents, for which the 
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from 
the anticipated average use levels in foods’ (JECFA, 2006). 
In the absence of more accurate information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a modified theoretical added maximum daily intake (mTAMDI) 
approach based on the normal use levels reported by Industry. 
As information on use levels for the flavouring substances has not been requested by the JECFA or 
has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the 
mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on 
use levels in order to finalise the evaluation. 
Threshold of 1.5 µg / capita per Day (Step B5) Used by the JECFA 
The JECFA uses the threshold of concern of 1.5 g / capita per day as part of the evaluation 
procedure: 
‘The Committee noted that this value was based on a risk analysis of known carcinogens which 
involved several conservative assumptions. The use of this value was supported by additional 
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information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the 
Committee, flavouring substances for which insufficient data are available for them to be evaluated 
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 µg / capita per day 
would not be expected to present a safety concern. The Committee recommended that the Procedure 
for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be amended to include 
the last step on the right-hand side of the original procedure (‘Do the conditions of use result in an 
intake greater than 1.5 µg per day?’) (JECFA, 1999).  
Consistent with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel 
does not make use of this threshold of 1.5 µg per person per day. 
Genotoxicity 
As reflected in the Opinion of SCF (SCF, 1999), the Panel has in its evaluation focussed on a possible 
genotoxic potential of the flavouring substances or of structurally related substances. Generally, 
substances for which the Panel has concluded that there is an indication of genotoxic potential in vitro 
will not be evaluated using the EFSA Procedure until further genotoxicity data are provided. 
Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated through 
the Procedure. 
Specifications 
Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of 
JECFA, as the Panel requests information on e.g. isomerism. 
Structural Relationship  
In the consideration of the JECFA evaluated substances, the Panel will examine the structural 
relationship and metabolism features of the substances within the flavouring group and compare this 
with the corresponding FGE. 
1. History of the Evaluation of the Substances in the present FGE 
At its 68th meeting, the JECFA evaluated a group of 15 flavouring substances consisting of aliphatic, 
acyclic and alicyclic terpenoid tertiary alcohols and structurally related substances. Two were not in 
the Register and seven tertiary alcohols [FL-no: 02.035, 02.037, 02.042, 09.086, 09.227, 09.232 and 
09.509] have been considered in FGE.89 (EFSA, 2009a). The remaining six substances have 
originally been considered by EFSA in FGE.90 (EFSA, 2010). 
FGE Opinion adopted 
by EFSA 
Link  No. of candidate 
substances 
FGE.90 15 February 2010 http://www.efsa.europa.eu/en/scdocs/scdoc/1336.htm 6 
FGE.90Rev1   6 
 
The present revision of FGE.90, FGE.90Rev1 includes the consideration of additional toxicity data 
provided for one representative substance anhydrolinalool oxide (5) [FL-no: 13.097] to be considered 
in FGE.75Rev1. The data provided are a 90-day study (Bauter, 2013). The new information will 
support the re-evaluation of 6-hydroxydihydrotheaspirane [FL-no: 13.076] and 6-
acetoxydihydrotheaspirane [FL-no: 13.087]. 
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2. Presentation of the Substances in the JECFA Flavouring Group 
2.1. Description 
2.1.1. JECFA Status 
The JECFA has evaluated a group of 15 flavouring substances consisting of aliphatic, acyclic and 
alicyclic terpenoid tertiary alcohols and structurally related substances (JECFA, 2008a). 
2.1.2. EFSA Considerations 
Two of the JECFA evaluated substances are not in the Register ((±)-ethyl 2-hydroxy-2-
methylbutyrate, JECFA no: 1651 and (±)-ethyl 2-hydroxy-3-methylbutyrate, JECFA no: 1652). Seven 
tertiary alcohols [FL-no: 02.035, 02.037, 02.042, 09.086, 09.227, 09.232 and 09.509] have been 
considered in FGE.89. Therefore, this consideration only deals with six substances. 
The Panel concluded that the six substances [FL-no: 02.018, 02.245, 02.250, 02.251, 13.076 and 
13.087] are structurally related to the group of aliphatic, alicyclic and aromatic saturated and 
unsaturated tertiary alcohols, aromatic tertiary alcohols and their esters evaluated by EFSA in the 
Flavouring Group Evaluation 18, Revision 3 (FGE.18Rev3). The latter 2 substances [FL-no: 13.076] 
and [FL-no: 13.087] are also structurally related to anhydrolinalol oxide (5) [FL-no: 13.097] evaluated 
in FGE.75 Revision 1. 
2.2. Isomers 
2.2.1. Status 
The following four substances [FL-no: 02.018, 02.250, 13.076 and 13.087] have a chiral centre and 
two substances [FL-no: 02.018 and 02.251] can exist as geometrical isomers. 
2.2.2. EFSA Considerations 
Information about the stereoisomeric composition has not been specified for two substances [FL-no: 
13.087 and 02.251]. 
Adequate specifications are available for four out of six materials of commerce. For substance [FL-no: 
02.251] information on the stereoisomeric composition and for substance [FL-no: 13.087] the identity 
of the isomers and the stereoisomeric composition needs to be specified. 
2.3. Specifications 
2.3.1. JECFA Status 
The JECFA specifications are available for all six substances. 
2.3.2. EFSA Considerations 
The European Flavouring Industry has submitted specifications for all six substances commercially 
used in Europe. (EFFA, 2006; EFFA, 2010;). Although the JECFA specifications are available, the 
specifications used in this consideration are those submitted by the Industry (see Table 3). 
Specifications including complete purity criteria and identity tests are available for all six substances 
(see Section 1.2).  
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3. INTAKE ESTIMATIONS 
3.1. JECFA Status 
For all six substances evaluated through the JECFA Procedure intake data are available for the EU. 
3.2. EFSA Considerations 
For the six substances [FL-no: 02.018, 02.245, 02.250, 02.251, 13.076 and 13.087] normal and 
maximum use levels have been provided by the Flavour Industry (EFFA, 2006; EFFA, 2007; EFFA, 
2010;) in accordance with the Commission Regulation (EC) No 1565/2000 , see Table 1. Based on the 
normal use levels, mTAMDI figures (see Table 2) can be calculated for these six substances (for 
calculation of mTAMDI figures, see e.g. FGE.03, Annex II (EFSA, 2004)). 
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Table 1:  Normal and Maximum use levels (mg/kg) available for the JECFA evaluated substances in FGE.90, Revision 1 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
02.018 2 
8 
- 
- 
2 
8 
- 
- 
- 
- 
200 
500 
2 
7 
2 
6 
- 
- 
- 
- 
- 
- 
- 
- 
1 
5 
- 
- 
2 
5 
30 
100 
2 
10 
- 
- 
02.245 - 
- 
- 
- 
- 
- 
0.5 
1.5 
0,5 
1.5 
0.5 
1.5 
- 
- 
1 
3 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.2 
0.5 
0.2 
0.5 
- 
- 
0.5 
1.5 
02.250 0.0005 
0.025 
0.0005 
0.025 
0.005 
0.25 
0.005 
0.025 
0.005 
0.025 
0.05 
2.5 
- 
- 
0.005 
0.25 
0.0005 
0.025 
0.0005 
0.025 
- 
- 
- 
- 
0.0005 
0.025 
- 
- 
0.05 
2.5 
0.05 
2.5 
0.0005 
0.025 
0.0005 
0.025 
02.251 0.0005 
0.0125 
0.0005 
0.0125 
0.005 
0.125 
0.005 
0.0125 
0.005 
0.0125 
0.05 
1.25 
- 
- 
0.005 
0.125 
0.0005 
0.0125 
0.0005 
0.0125 
- 
- 
- 
- 
0.0005 
0.0125 
- 
- 
0.05 
1.25 
0.05 
1.25 
0.0005 
0.0125 
0.0005 
0.0125 
13.076 1 
10 
- 
- 
1 
5 
- 
- 
- 
- 
100 
1000 
2 
4 
4 
6 
1 
2 
1 
2 
- 
- 
- 
- 
1 
2 
- 
- 
10 
50 
10 
50 
1 
5 
- 
- 
13.087 1 
8 
- 
- 
1 
80 
- 
- 
- 
- 
10 
20 
2 
7 
2 
6 
- 
- 
- 
- 
- 
- 
- 
- 
1 
10 
- 
- 
1 
5 
2 
10 
1 
5 
- 
- 
 
 
 
Table 2:  Estimated intakes based on the MSDI- and the mTAMDI approach 
FL-no EU Register name MSDI – EU (g /capita 
per day) 
MSDI – USA (g / 
capita per day) 
mTAMDI (g / person 
per day) 
Structural class Threshold of concern 
(µg / person per day) 
02.018 Nerolidol 43 23 7000 Class I 1800 
02.245 2,3,4-Trimethyl-3-pentanol 0.49 ND 220 Class I 1800 
02.250 2,4,8-Trimethyl-7-nonen-2-ol 3.0 0.1 19 Class I 1800 
02.251 2,4,8-Trimethyl-3,7-nonadien-2-ol 3.0 1 19 Class I 1800 
13.076 6-Hydroxydihydrotheaspirane 0.12 0.05 6700 Class II 540 
13.087 6-Acetoxydihydrotheaspirane 0.12 ND 940 Class II 540 
ND: No intake data available 
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4. GENOTOXICITY DATA 
4.1. Genotoxicity Studies – Text taken4 from the JECFA (JECFA, 2008a) 
JECFA did not review any genotoxicity studies related to the substances considered in this opinion. 
They did, however, comment on one chromosomal aberration assay on linalyl acetate [FL-no: 09.013], 
a supporting substance that gave negative results and concluded that this substance was not of safety 
concern. JECFA also commented on the closely related substance linalyl proprionate which is not in 
the Register, but gave negative results in an Ames test when tested at levels of up to 5,000 
microgram/plate +/- S9 (JECFA, 2008a). 
4.2. Genotoxicity Studies – Text taken5 from EFSA FGE.18Rev3 (EFSA, 2015) 
In vitro/in vivo 
Data from in vitro tests are available for four candidate [FL-no: 02.052, 02.041, 02.123 and 02.168] 
and for eight supporting substances [FL-no: 01.002, 01.008, 02.013, 02.014, 02.015, 02.097, 09.013 
and 09.830]. Data from in vivo tests are available for two candidate [FL-no: 02.052 and 02.123] and 
for three supporting substances [FL-no: 01.008, 02.013 and 02.015].  
2-Methylpropan-2-ol [FL-no: 02.052] was negative in reversion tests in Salmonella Typhimurium 
TA1535, TA1537, TA98 and TA100, without and with metabolic activation by rat and hamster liver 
S9 (Zeiger et al., 1987). A borderline (less than two-fold) increase in revertants in strain TA1535 was 
observed in two other studies (Haworth et al., 1981a; Haworth et al., 1981b), which were not available 
for evaluation. A marginal increase in sister chromatid exchange (SCE) was reported from two studies 
with Chinese hamster ovary (CHO) cells, which could not be evaluated because the papers were 
submitted incompletely (Putman, 1985; Thilagar et al., 1981). A borderline increase in mutant 
frequency was observed in mouse-lymphoma TK +/- cells in a single test in the absence of metabolic 
activation, whereas negative results were obtained in repeated experiments with S9 (McGregor et al., 
1988). Again, similar results are quoted in the summary of an unpublished study not available for 
evaluation (Kirby et al., 1981). Finally, a slight increase in petite (mitochondrial) mutations was 
reported in yeast after treatment with 2-methylpropan-2-ol (Jiménez et al., 1988), but this effect is not 
considered relevant for genotoxicity assessment. 
In vivo, 2-methylpropan-2-ol gave clearly negative results in a rat bone marrow micronucleus test, 
after intraperitoneal (i.p.) administration of a range of doses (six doses from 39 to 1,250 mg/kg body 
weight (bw)), which reached complete lethality at the highest dose (NTP, 1997). Negative results were 
also obtained in the mouse peripheral blood micronucleus assay, after 13 weeks of oral exposure to 
3,000–40,000 ppm in drinking water. There was no deviation in the PCE/NCE ratio in treated animals, 
but signs of general toxicity were observed at the two highest doses, indicating significant systemic 
exposure (NTP, 1995). In another study, 2-methylpropan-2-ol was negative in the mouse bone marrow 
micronucleus assay when given by i.p. injections at doses up to 1,250 mg/kg bw (three daily 
administrations) (NTP, 1996). The alleged positive result obtained with 2-methylpropan-2-ol in a rat 
bone marrow chromosomal aberration test after oral administration of 1/5 of the LD50 (Barilyak and 
Kozachuk, 1988) is considered inconclusive, because the result is not adequately supported by 
experimental data. 
                                                     
 
4  The text is taken verbatim from the indicated reference source, but text related to substances not included in the present 
FGE has been removed. 
5  The text is taken verbatim from the indicated reference source, but text related to substances not included in the present 
FGE has been removed. 
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Terpineol [FL-no: 02.230] (the mixture of alpha-terpineol, beta-terpineol, delta-terpineol and 
gamma-terpineol) 
Terpineol was tested negative in a rec assay in Bacillus subtilis (Oda et al., 1978).  
alpha-Terpineol [FL-no: 02.014] was reported to give weakly positive results (as a dose-dependent 
increase in mutation frequency both with and without S9 activation with a maximum increase of 2.2-
fold compared with the control) in an Ames-type mutagenicity assay in one (TA102) of four 
Salmonella Typhimurium strains tested (TA97a, TA98, TA100, TA102). alpha-Terpineol was 
incorporated into agar plates up to 2,500 microgram/plate, either with or without S9 metabolic 
activation (Gomes-Carneiro et al., 1998). 
In other studies, alpha-terpineol gave consistently negative results in Ames assays in S. Typhimurium 
strains TA98, TA100, TA1535, TA1537,and TA1538, either with or without S9 metabolic activation 
(Heck et al., 1989; Florin et al., 1980; Lorillard, 1983). 
In an in vivo/in vitro study designed to investigate the mutagenicity of the metabolites of beta-
terpineol [FL-no: 02.097], Sprague–Dawley rats were administered a single dose of 0.5 ml (452 mg) 
of beta-terpineol by gavage and the urine was collected for 24 h. The urine (500 µl) was hydrolysed 
with beta-glucuronidase. Hydrolysed and unhydrolysed urine samples, ether extracts of the urine, and 
aqueous fractions of the urine–ether extracts were then separately incubated with S. Typhimurium 
strains TA98 and TA100 without S9 activation. Neither beta-terpineol, nor any of the urinary solutions 
isolated from the urine of rats given 452 mg doses of beta-terpineol, showed any evidence of 
mutagenicity in either TA98 or TA100 without metabolic activation (Rockwell and Raw, 1979). 
In gene mutation tests in mouse lymphoma cells, alpha-terpineol was non-mutagenic when applied at 
doses up to 250 nl/ml (with S9) and 300 nl/ml (without S9) (Lorillard, 1982); negative results were 
also obtained in another study in which alpha-terpineol was tested up to 460 nl/ml (with S9) and 380 
nl/ml (without S9) (Kirby et al., 1984). Based on the negative results obtained in gene mutation tests 
in mammalian cells, and in view of the sensibility of the TK +/- system to mutagens specifically active 
toward the S. Typhimurium strain TA102, the Panel concluded that alpha-terpineol does not raise 
concern for genotoxicity. 
Overall, 2-methylpropan-2-ol provided an equivocal evidence of genotoxicity in some in vitro assays, 
whereas it was clearly negative in vivo in cytogenetic tests conducted up to the maximum tolerated 
dose. The overall weight of the experimental evidence does not raise concern for in vivo genotoxicity. 
2-Methylbut-3-en-2-ol [FL-no: 02.123] was reported to be negative in two bacterial gene mutation 
tests and in an in vivo micronucleus test, however, the unpublished study reports are not available for 
re-evaluation. 
For the other substances in FGE.18Rev1, the available data considered valid do not give rise to any 
safety concerns with respect to genotoxicity.  
For a summary of in vitro/in vivo genotoxicity data, considered by EFSA in FGE.18Rev3 see Table 4 
and Table 5. 
5. A 90-Day Study for 6-acetoxydihydrotheaspirane [FL-no: 13.087] 
A 90-day single dose study on [FL-no: 13.087] is available (Griffiths, 1979). The numbers of 
parameters examined in this study, although state of the art at that time, are, however, limited 
compared to modern OECD guidelines. 
Griffiths (1979) did a 90-day study of 3 mg/kg per day of 6-acetoxydihydrotheaspirane by gavage in 
male and female Sprague–Dawley rats  (n = 15 per group) of initial body weight 70–95 g (in an 
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aqueous solution kept at 30–350C to hold the compound in solution). The only difference between 
controls and treated rats was a 4.7% decrease in red bloods cells (and haemoglobin and haematocrit) in 
females. During the 3 months of treatment, no other changes were observed in body weight, 
haematology, serum chemistry and microscopy of the organs. Since an OECD guideline 90-day study 
in rats on a supporting compound is available, the more limited Griffith (1979) study will not be used 
for safety assessment.   
6. A 90-Day Study on anhydrolinalool oxide [FL-no: 13.097] evaluated in FGE.75Rev1 
(EFSA, 2015) 
A new guideline study on a supporting substance, anhydrolinalool oxide [FL-No: 13.097] is now 
available.  It supports the evaluation of 6-hydroxydihydrotheaspirane [FL-No: 13.076] and 
acetoxydihydrotheaspirane [FL-No: 13.087]. This OECD TG 408 compliant 90-day study in rats is 
described extensively in FGE75Rev1.  A NOAEL of 52 mg/kg bw per day could be derived from the 
results.  
6.1. EFSA Considerations 
The Panel concluded that the data available do not preclude evaluation of the six substances [FL-no: 
02.018, 02.245, 02.250, 02.251, 13.076 and 13.087] through the Procedure. 
7. Application of the Procedure 
7.1. Application of the Procedure to Aliphatic, Acyclic and Alicyclic Terpenoid Tertiary 
Alcohols and Structurally Related Substances by JECFA (JECFA, 2008a): 
According to the JECFA, four of the substances belong to structural class I and two to structural class 
II using the decision tree approach presented by Cramer et al. (1978). 
The JECFA concluded all six substances at step A3 in the JECFA Procedure – meaning that the 
substances are expected to be metabolised to innocuous products (step 2) and concluded that the 
intakes for all substances are below the thresholds for their structural classes I and II (step A3).  
The evaluations of the six substances are summarised in Table 7. 
7.2. Application of the Procedure to Aliphatic, Alicyclic and Aromatic Saturated and 
Unsaturated Tertiary Alcohols, Aromatic Tertiary Alcohols and their Esters evaluated 
by EFSA (EFSA, 2015): 
Thirty candidate substances were evaluated in FGE.18Rev3; 20 substances are classified into 
structural class I, 11 substances into structural class II and one candidate substance is classified into 
structural class III according to the decision tree approach presented by Cramer et al. (1978).  
Twenty-eight substances were evaluated at step A3, i.e. the substances are expected to be metabolised 
to innocuous products (step 2) and the estimated daily intake is below the threshold for the structural 
classes I and II (step A3). 
Four of the candidate substances were evaluated at step B4, but no NOAEL could be derived for any 
of the four candidate substances and accordingly additional data for these substances were required. 
The evaluations of the 32 substances are summarised in Table 8. 
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7.3. EFSA Considerations  
The Panel agrees with the way the application of the Procedure has been performed by the JECFA for 
four of the six aliphatic, acyclic and alicyclic terpenoid tertiary alcohols and structurally related 
substances evaluated by the JECFA [FL-no: 02.018, 02.245, 02.250 and 02.251]. For the remaining 
two substances [FL-no: 13.076 and 13.087], no metabolism data are available, neither for the 
substances themselves nor for related substances. Therefore, in contrast to the JECFA, the Panel 
cannot conclude that these substances are metabolised to innocuous products and they should 
accordingly be evaluated via the B-side of the Procedure scheme. A NOAEL of 52 mg/kg bw was 
derived from a 90-day study in rats for the structurally related substance anhydrolinalool oxide. 
Compared with an exposure estimate of 0.12 µg /capita per day for both [FL-no: 13.076 and 13.087] a 
margin of safety of more than 26 × 106 can be calculated. Accordingly, for these two substances the 
Panel concluded that they are not of safety concern at estimated level of intake as flavouring 
substances based on the MSDI approach. 
8. CONCLUSION 
The JECFA has evaluated a group of 15 flavouring substances consisting of aliphatic, acyclic and 
alicyclic terpenoid tertiary alcohols and structurally related substances. 
Two of the JECFA evaluated substances are not in the Register ((±)-ethyl 2-hydroxy-2-
methylbutyrate, JECFA no: 1651 and (±)-ethyl 2-hydroxy-3-methylbutyrate, JECFA no: 1652). Seven 
tertiary alcohols [FL-no: 02.035, 02.037, 02.042, 09.086, 09.227, 09.232 and 09.509] have been 
considered in FGE.89. Therefore, this consideration only deals with six substances. 
The Panel concluded that the six substances [FL-no: 02.018, 02.245, 02.250, 02.251, 13.076 and 
13.087] are structurally related to the aliphatic, alicyclic and aromatic saturated and unsaturated 
tertiary alcohols, aromatic tertiary alcohols and their esters evaluated by EFSA in the Flavouring 
Group Evaluation 18, Revision 3 (FGE.18Rev3) or FGE.75, Revision 1 (FGE.75Rev1).  
The Panel agrees with the way the application of the Procedure has been performed by the JECFA for 
four of the six substances [FL-no: 02.018, 02.245, 02.250 and 02.251]. For the remaining two 
substances [FL-no: 13.076 and 13.087], no metabolism data are available, neither for the substances 
themselves nor for related substances. Therefore, in contrast to the JECFA, the Panel cannot conclude 
that these substances are metabolised to innocuous products and they should accordingly be evaluated 
via the B-side of the Procedure scheme. A NOAEL of 52 mg/kg bw was derived from a 90-day study 
in rats for the structurally related substance anhydrolinalool oxide. Compared with an exposure 
estimate of 0.12 µg / capita per day for both [FL-no: 13.076 and 13.087] a margin of safety of more 
than 26 × 106 can be calculated. Accordingly, the Panel agrees with the JECFA conclusion ‘No safety 
concern at estimated level of intake as flavouring substances’ based on the MSDI approach. In order to 
determine whether the conclusion for the six JECFA evaluated substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications.  
Adequate specifications are available for four out of six materials of commerce. For substance [FL-no: 
02.251], information on the stereoisomeric composition has not been specified and for substance [FL-
no: 13.087], the identity of the isomers needs to be specified. 
Thus, for four substances [FL-no: 02.018, 02.245, 02.250 and 13.076] the Panel agrees with the 
JECFA conclusion ‘No safety concern at estimated level of intake as flavouring substances’ based on 
the MSDI approach. 
For the six substances, use levels have been provided by the Industry [FL-no: 02.018, 02.245, 02.250, 
02.251, 13.076 and 13.087]. The mTAMDI figures calculated for three of the six substances [FL-no: 
02.018, 13.076 and 13.087] are above the threshold of concern for their structural classes. For these 
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substances, more reliable exposure data are needed. On the basis of such data the substances should be 
reconsidered using the Procedure.  
Thus, for two substances [FL-no: 02.251 and 13.087] the Panel has reservations (missing information 
on stereoisomerism and mixture of isomers).  
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Table 3:  Specification Summary of the Substances in the JECFA Flavouring Group of Aliphatic, Acyclic and Alicyclic Terpenoid Tertiary Alcohols and 
Structurally Related Substances (JECFA, 2008b) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys. form 
Mol. 
formula 
Mol. weight 
Solubility (a) 
Solubility in ethanol 
(b) 
Boiling point, °C 
(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index (d) 
Spec.gravity 
(e) 
EFSA comments /  
Reference for 
specifications 
02.018 
1646 
Nerolidol OH 2772 
67 
7212-44-4 
Liquid 
C15H26O 
222.38 
Slightly soluble 
Soluble 
276 
 
NMR 
96% to 100% 
1.478-1.483 
0.870-0.876 
 
Specifications (EFFA, 
2006). 34-44% Cis 
nerolidol. 
54-64% Trans nerolidol. 
02.245 
1643 
2,3,4-Trimethyl-3-pentanol 
OH  
3903 
 
3054-92-0 
Liquid 
C8H18O 
130.23 
Insoluble 
Soluble 
156.5 
 
IR NMR MS 
97 % 
1.440 
0.850 
 
Specifications (EFFA, 
2010). 
02.250 
1644 
2,4,8-Trimethyl-7-nonen-2-ol OH
 
4212 
 
437770-28-
0 
Liquid 
C12H24O 
184.32 
Insoluble 
Soluble 
60-70 (2 hPa) 
 
IR NMR 
96 % 
1.448-1.456 
0.845-0.855 
 
Racemate (EFFA, 2010). 
Specifications ().; (EFFA. 
2010). 
02.251 
1645 
2,4,8-Trimethyl-3,7-nonadien-2-ol OH
 
4211 
 
479547-57-
4 
Liquid 
C12H22O 
182.31 
Insoluble 
Soluble 
70-72 (2 hPa) 
 
NMR 
96 % 
1.463-1.471 
0.857-0.867 
 
Mixture of (Z)- and (E)-
isomer (EFFA. 2010). 
Specifications (EFFA. 
2010). 
13.076 
1648 
6-Hydroxydihydrotheaspirane 
O
OH
 
3549 
11917 
65620-50-0 
Liquid 
C13H24O2 
212.33 
Very slightly soluble 
Soluble 
273.4 
 
MS 
97% to 100% 
1.481-1.487 
0.999-1.005 
 
Specifications (EFFA, 2006; 
EFFA. 2010). 46-53% trans 
isomer (CASrn 65620-50-0), 
44-51% cis isomer (CASrn 
57967-68-7) , 0-2% 
Isospiranol (CASrn 54344-
69-3). 
13.087 
1647 
6-Acetoxydihydrotheaspirane 
O
O
O
3651 
 
57893-27-3 
Solid 
C15H26O3 
254.37 
Insoluble 
Soluble 
293.7 
33-55 
IR NMR 
96% to 100% 
n.a 
n.a 
 
Specifications (EFFA, 2006; 
EFFA. 2010). According to 
EFFA Assay min is 96-
100% (Sum of two isomers). 
(a) Solubility in water, if not otherwise stated. 
(b) Solubility in 95% ethanol, if not otherwise stated. 
(c) At 1013.25 hPa, if not otherwise stated. 
(d) At 20°C, if not otherwise stated. 
(e) At 25°C, if not otherwise stated. 
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Genotoxicity Data Tables 
No genotoxicity data available for the substances in this FGE.90 
Table 4:  Genotoxicity Data (in vitro) EFSA / FGE.18Rev2 (EFSA, 2011). Substances listed in brackets are the JECFA evaluated supporting substances in 
FGE.18Rev2 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
2-Methylpropan-2-ol [02.052] Ames test S. Typhimurium 
TA98; TA100; TA1535; 
TA1537; TA1538 
0.1, 0.5, 2.5, 5, 10 µl/plate 
(7800 µg/plate) 
Questionable(a) (Haworth et al., 1981a) Unpublished GLP study. According to the conclusion of the report, the test 
substance ‘did cause a weak but significant increase in TA1535 revertants per 
plate in both the presence and absence of rat liver microsomes’. However, this 
result cannot be re-evaluated because the corresponding page with results on 
TA1535 in Table format is lacking. 
 Ames test S. Typhimurium 
TA98; TA100; TA1535; 
TA1537; TA1538 
probably 1 to 10 µl/plate 
(7800 µg/plate) 
(corresponding pages of the 
report are lacking) 
Questionable(a) (Haworth et al., 1981b) Unpublished GLP study. According to the conclusion of the report, the test 
substance (purity 99.9 %) ‘did not cause a significant increase in the number of 
revertants per plate in any of the tester strains with or without metabolic 
activation. It should be noted, however, that there was a slight increase in TA1535 
revertants per plate observed in the presence and absence of rat liver 
microsomes’. However, this result cannot be re-evaluated because 15 pages with 
all results in Table format are lacking. 
 Ames test S. Typhimurium 
TA98; TA100; TA1535; 
TA1537 
10,000 µg/plate Negative(a) (Zeiger et al., 1987) Non-GLP study roughly in accordance with OECD guideline 471. There was a 
slight increase in TA1535 revertants per plate observed in the presence and 
absence of rat and hamster liver microsomes. This effect is dose-related only with 
hamster liver S9. Overall, the effects were less than twice compared to control. 
The study is considered valid. 
 Yeast 
mitochondrial 
mutation assay 
Several Saccharomyces 
strains 
4% Positive (Jiménez et al., 1988) This non-GLP study was not in accordance with OECD guideline No. 480 (1986), 
and the study protocol does not belong to standard protocols used in routine 
testing. However, the result is considered valid since main details of method and 
results are reported. Endpoint not relevant for genotoxicity. 
 Forward mutation 
assay 
Mouse lymphoma  
L5178Y TK +/- 
0, 1000, 2000, 3000, 4000, 
5000 µg/ml 
Negative(a) (McGregor et al., 1988) Non-GLP study in accordance with OECD guideline 476 (1984). Study is 
considered valid. 
 
Forward mutation 
assay 
Mouse lymphoma  
L5178Y TK +/- 
1.3 to 100 µl/ml 
(78,000 µg/ml) 
Negative (Kirby et al., 1981) Unpublished GLP study. According to the report's summary, test substance of 
high (99.9 %) purity did not induce any detectable increases in the mutant 
frequencies in the presence and absence of S9-mix. When cultures were tested in 
the presence of S9-mix with less pure test substance none of the cultures 
exhibited increases in mutant frequency. Without S9-mix this test substance did 
appear to induce an increase in the mutant frequency of cultures treated with the 
higher doses, but a dose-related response was not evident. In addition, in only one 
of two experiments was a greater than two-fold increase in mutant frequency 
observed. However, this result cannot be re-evaluated because 47 pages with all 
results in Table format are lacking in the report submitted. 
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Table 4:  Genotoxicity Data (in vitro) EFSA / FGE.18Rev2 (EFSA, 2011). Substances listed in brackets are the JECFA evaluated supporting substances in 
FGE.18Rev2 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
 
Chromosomal 
aberration 
Chinese hamster ovary cells 160 to 5000 microgram/ml Negative (NTP, 1984) Limited validity. This non-GLP study was in accordance with OECD guideline 
No. 473 (1983) except that only a single harvest time was used, however, the 
study protocol does not fully meet the criteria of the revised guideline from 1997. 
According to the version from 1997, a single sampling time should be equivalent 
to about 1.5 normal cell cycle lengths, duplicate cultures should be used at each 
concentration and 200 metaphases should be scored per concentration. 
 
Sister chromatid 
exchange 
Chinese hamster ovary cells 6 concentrations ranging from 
0.625 to 20 µl/ml 
(15,600 µg/ml) 
Negative (Putman, 1985) Unpublished GLP study. According to the report's summary, test substance of 
high (99.9 %) purity caused a significant increase in sister chromatid exchanges at 
the high dose only in the assay without S9 and at the two highest doses in the 
assay with S9, however, the test article did not meet the criteria for a positive 
response (at least two-fold increase or a significant positive dose-response over at 
least three doses). However, this result cannot be re-evaluated because pages with 
all results in Table format are lacking in the report submitted. 
 
Sister chromatid 
exchange 
Chinese hamster ovary cells 20 µl/ml 
(15,600 µg/ml) 
Negative (Thilagar et al., 1981) Unpublished GLP study is considered valid. A marginal increase in SCE 
frequency was observed in the tests with and without S9, while only the highest 
concentration without S9 resulted in a significant increase. Thus, the test article 
did not meet the criteria for a positive response (at least two-fold increase or a 
significant positive dose-response over at least three doses). (All relevant tables 
were submitted) 
2-Methylbutan-2-ol [02.041] Mutagenicity 
assays 
S. Typhimurium 
TA1535; TA1537; 
TA1538; 
S. cerevisiae 
NR Negative (Dow Chemical Company, 
1982) 
Very short abstract only. 
 Sister chromatid 
exchange 
 
Chinese hamster ovary cells 160, 500, 1600, 5000 µg/ml Positive(c)
Negative(b) 
(NTP, 1997)  
 Sister chromatid 
exchange 
 
Chinese hamster ovary cells 2000, 3000, 4000, 5000 µg/ml Negative(a) (NTP, 1997)  
2-Methylbut-3-en-2-ol [02.123] Ames test S. Typhimurium 
TA98; TA100; TA1535; 
TA1537 
20 - 5000 µg/plate Negative(a) (BASF, 1989) Summary in IUCLID data set only. According to this summary, the assay was not 
in compliance with GLP but in accordance with OECD guideline 471. The 
unpublished study report is not available for re-evaluation. 
 Liquid suspension 
assay 
S. Typhimurium  
TA98; TA100 
20 - 5000 µg/plate Negative(a) (BASF, 1991) Summary in IUCLID data set only. According to this summary, the assay was not 
in compliance with GLP but in accordance with OECD guideline 471. The 
unpublished study report is not available for re-evaluation. 
Isophytol [02.168] Ames test S. Typhimurium 
TA97; TA98; TA100; 
TA1535 
 100, 333, 1000, 3333, 10000 
microgram/plate 
Equivocal(a) (NTP, 1994) This non-GLP study is considered valid. It is in accordance with OECD guideline 
No. 471 (1983). The study is published in the Web and the report contains 
sufficient details. 
 Ames test S. Typhimurium TA97, 
TA98, TA100, and TA1535 
five doses from 100 to 10000 
microgram/plate 
Negative (NTP, 2000) This non-GLP study is considered valid. It is in accordance with OECD guideline 
No. 471 (1983). The study is published in the Web and the report contains 
sufficient details. 
(Linalool [02.013]) Ames 
test(modified) 
S. Typhimurium 
TA100 
3 µl/2 ml 
(2610 µg/2ml) 
incubation volume 1 mg/plate 
Negative(a) (Eder et al., 1980)  
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Table 4:  Genotoxicity Data (in vitro) EFSA / FGE.18Rev2 (EFSA, 2011). Substances listed in brackets are the JECFA evaluated supporting substances in 
FGE.18Rev2 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
 Ames test S. Typhimurium 
TA92; TA94; TA98; 
TA100; TA1535; TA1537 
(1000 µg/plate) Negative(a) (Ishidate et al., 1984)  
 Ames test S. Typhimurium 
TA98; TA100 
100 µl 
(87000 µg) 
Negative(a) (Rockwell and Raw, 1979)  
 Ames test S. Typhimurium 
TA98; TA100; TA1535; 
TA1537; TA1538 
10,000 nl/plate 
(8700 µg/plate) 
Negative(a) (Heck et al., 1989) Some important details of method and results are not reported. Thus, the validity 
of this study cannot be evaluated. 
 Chromosomal 
aberration assay 
Chinese hamster 
fibroblasts 
0.25 mg/ml 
(250 µg/ml) 
Negative(a) (Ishidate et al., 1984)  
 Unscheduled 
DNA synthesis 
Rat hepatocytes 50 nl/ml 
(43.6 µg/ml) 
Negative (Heck et al., 1989) Some important details of method and results are not reported. Thus, the validity 
of this study cannot be evaluated. 
 Mutation assay E. coli  
WP2 uvrA 
1 mg/plate 
(1000 µg/plate) 
Negative (Yoo, 1986) In Japanese (only summary and tables in English). Thus, the validity cannot be 
evaluated. 
 Recassay B. subtilis 
H17 (rec+); M45 (rec-) 
17 µg Negative (Oda et al., 1979)  
 Recassay B. subtilis 
H17 (rec+); M45 (rec-) 
10 µl/disk 
(8700 µg/disk) 
Positive (Yoo, 1986) In Japanese (only summary and tables in English). Thus, the validity cannot be 
evaluated. 
 Mammalian cell 
mutation 
Mouse Lymphoma  
L5178Y TK+/- 
3.9 to 300 nl/ml Negative(b)
Positive© 
(Heck et al., 1989) Some important details of method and results are not reported. Thus, the validity 
of this study cannot be evaluated. 
 Sister chromatid 
exchange 
Chinese hamster ovary cells 1000 µM 
(154,250 µg) 
Negative(a, d) (Sasaki et al., 1989)  
(Linalyl acetate [09.013]) Ames test S.Typhimurium TA98; 
TA100; TA1535; TA1537; 
TA1538 
25,000 nl/plate 
(22575µg/plate) 
Negative(a) (Heck et al., 1989) Some important details of method and results are not reported. Thus, the validity 
of this study cannot be evaluated. 
 Unscheduled 
DNA synthesis 
Fischer or SD rat 
hepatocytes 
300 nl/ml 
(271 µg/ml) 
Negative (Heck et al., 1989) Some important details of method and results are not reported. Thus, the validity 
of this study cannot be evaluated. 
 Recassay B. subtilis 
H17 (rec+); M45 (rec-) 
18 µg Negative (Oda et al., 1979)  
 Chromosome 
aberration 
Peripheral human 
lymphocytes 
180 µg/ml Negative(a) (Bertens and van de Waart, 
2000) 
 
(alpha-Terpineol [02.014]) Ames test S. Typhimurium 
TA98; TA100; TA1535; 
TA1537; TA1538 
10,000 µg/plate Negative (Heck et al., 1989) Some important details of method and results are not reported. Thus, the validity 
of this study cannot be evaluated. 
 Ames test S. Typhimurium 
TA97a; TA98; TA100;  
 
2500 µg/plate  
Negative 
 
(Gomes-Carneiro et al., 
1998) 
The study is considered valid. A slight but dose-related response was noted with 
TA102 with and without the use of metabolic activation.  
 
  TA102 2500 µg/plate Weakly 
positive(e) 
  
 Ames test S. Typhimurium 
TA98; TA100; TA1535; 
TA1537; TA1538 
1000 µg/plate Negative(a) (National Cancer Institute, 
1983) 
 
 Ames test S.Typhimurium 
TA98; TA100; TA1535; 
TA1537; TA1538 
10,000 µg/plate Negative(a) (Lorillard, 1983)  
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Table 4:  Genotoxicity Data (in vitro) EFSA / FGE.18Rev2 (EFSA, 2011). Substances listed in brackets are the JECFA evaluated supporting substances in 
FGE.18Rev2 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
 Spot test S. Typhimurium 
TA98; TA100; TA1535; 
TA1537 
3 µmol/plate 
(463 µg/plate) 
Negative(a) (Florin et al., 1980)  
 Mammalian cell 
mutation 
Mouse Lymphoma  
L5178Y TK +/- 
0.5 µl/ml (467µg/ml) 
0.75µl/ml (700 µg/ml) 
Negative(c)
Negative(b) 
(Kirby et al., 1984)  
 Mammalian cell 
mutation 
Mouse Lymphoma  
L5178Y TK +/- 
300 nl/ml (280 µg/ml)  
250 nl/ml (233 µg/ml) 
Negative(a) (Heck et al., 1989) Some important details of method and results are not reported. Thus, the validity 
of this study cannot be evaluated. 
 Mammalian cell 
mutation 
Mouse lymphoma  
L5178Y TK +/- 
15.6 -250 nl/ml 
15.6 -300 nl/ml 
Negative(b)
Negative(c) 
(Lorillard, 1982)  
 Recassay S. cerevisiae NR Negative (Oda et al., 1979)  
(Terpinyl acetate [09.830]) Rec assay B. subtilis  
H17; M45 
19 µg Negative (Oda et al., 1979)  
(beta-Terpineol) [02.097]) Ames S. Typhimurium 
TA98; TA100 
100 µg  
(93,000 µg) 
Negative(a) (Rockwell and Raw, 1979)  
 Rec assay S. cerevisiae NR Negative(a) (Oda et al., 1979) Article does not specify alpha- or beta-terpineol
(1-Isopropyl-4-methylbenzene 
[01.002]) 
In vivo/in vitro 
Ames test 
S.Typhimurium TA98 and 
TA100 
0.5 ml (equivalent to 1,706 
mg/kg bw) administered to 
Sprague–Dawley rats, urine 
collected and tested in vitro 
Negative(e) (Rockwell and Raw, 1979)  
(Myrcene [01.008]) Ames test S. Typhimurium TA100; 
TA1535; TA97; TA98 
0, 33, 100, 333, 1000, 3333 
and 10,000 g/plate 
Negative(a) (NTP, 1999  
 Chromosome 
aberration 
Human lymphocytes 0, 100, 500 and 1000 g/ml Negative(a) (Kauderer et al., 1991)  
 Sister chromatid 
exchange 
Human lymphocytes 0, 100, 500 and 1000 g/ml Negative(a) (Kauderer et al., 1991)  
 HPRT assay V79 Chinese hamster cells 0, 100, 500 and 1000 g/ml Negative(a) (Kauderer et al., 1991)  
 Sister chromatid 
exchange 
V79 Chinese hamster cells 0, 100, 250 and 500 g/ml Negative(a) (Röscheisen et al., 1991)  
 Sister chromatid 
exchange 
HTC cells 0, 100, 250 and 500 g/ml Negative (Röscheisen et al., 1991)  
(Menthol [02.015]) Ames test  S Typhimurium TA92, 
TA100, TA94, TA98, 
TA1535, TA1537 
0, and 6 concentrations up to 
5000 µg/plate  
Negative(a)  (Ishidate et al., 1984) d,l-Menthol was used. The study is considered valid.  
 Ames test 
(preincubation 
method) 
S. Typhimurium TA1535, 
TA97, TA100, TA98 
3 - 666 µg/plate  Negative(a) (Zeiger et al., 1988) d,l-Menthol was used. The study is considered valid.  
 Ames test  S. Typhimurium TA2637, 
TA100, TA98 
0, 5 - 500 µg/plate  Negative(a)  (Nohmi et al., 1985) d,l-menthol was tested. The highest concentrations were cytotoxic. The study is 
considered valid. 
 Ames test  S. Typhimurium TA2637, 
TA100, TA98 
0, 20 - 500 µg/plate  Negative(a)  (Nohmi et al., 1985) l-menthol was tested. The highest concentrations were cytotoxic. The study is 
considered valid. 
 Ames test  S Typhimurium TA1537, 
TA1535, TA100, TA98 
0, 6.4, 32, 160, and 800 
µg/plate  
Negative(a)  (Andersen and Jensen, 
1984) 
No indication of which enantiomer was used. In the absence of metabolic 
activation, the highest concentration was cytotoxic. The study is considered valid. 
 Ames test  E. coli WP2 uvrA (Trp-) 100 - 800 µg/plate  Negative  (Yoo, 1986) l-Menthol was used. The article is not in English. The validity of the study cannot 
be evaluated. It is unclear whether metabolic activation or a control group was 
used. 
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Table 4:  Genotoxicity Data (in vitro) EFSA / FGE.18Rev2 (EFSA, 2011). Substances listed in brackets are the JECFA evaluated supporting substances in 
FGE.18Rev2 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
 Ames test  S. Typhimurium TA97A; 
TA98; TA100; TA102 
0, 5 - 800 µg/plate  Negative(a)  (Gomes-Carneiro et al., 
1998) 
(-)-Menthol was used. The range of concentrations tested varied between the 
different strains. Cytotoxicity was observed with the highest concentrations tested 
with TA97A and, in the presence of metabolic activation, the highest 
concentration tested with TA102. The study is considered valid. 
 Rec assay  B. subtilis H17, M45 Up to 10,000 µg/disk  Positive (Yoo, 1986) l-Menthol was used. Inhibition zone for rec- and rec+ was 42 and 23 mm, 
respectively. The article is not in English. It is not clear from the study whether 
metabolic activation, or a control group was used. The validity of this study 
cannot be assessed. The method (rec assay) has poor predictive value. 
 Rec assay  B. subtilis H17, M45 20 µg/disk  Negative (Oda et al., 1979) l-Menthol was used. The article is not in English. Only one concentration level is 
mentioned at a table. No data on metabolic activation or control group. The 
validity of this study cannot be evaluated. The method (rec assay) has poor 
predictive value. 
 Alkaline elution 
assay 
Rat hepatocytes  0, 0.1 - 1.3 mM (203.2 µg/ml4) Negative (Storer et al., 1996) The experiment employed d-Menthol. An increase in DNA breaks was only 
observed at concentrations associated with cytotoxicity. The authors concluded 
that this was a false-positive result. The study is considered valid.  
 Sister chromatid 
exchange 
Chinese hamster ovary cells 5 – 50 amd 0, 2 – 25 µg/ml3
0, 16 – 167 µg/ml 2 
Negative(a)  (Ivett et al., 1989) d,l-Menthol was used. The compound was tested up to toxic or nearly toxic 
concentration levels. The study is considered valid. 
 Sister chromatid 
exchange 
Human lymphocytes 0, 0.1, 1, 10 mM (1563 µg/ml4) Negative(a)  (Murthy et al., 1991) The study is considered valid. 
 Cytogenetic assay Human embryonic lung 
cells 
0, 0.1, 1, 10 µg/ml  Negative  (Food and Drug Research 
Laboratories, Inc., 1975) 
The report does not mention exogenous metabolic activation. The study is 
considered valid. 
 Chromosome 
aberration 
Chinese hamster fibroblasts 0 and three concentrations up 
to 200 µg/ml  
Negative(c)  (Ishidate et al., 1984) The maximum concentration (cytotoxic) was selected by a preliminary test. The 
study is considered valid. 
 Chromosome 
aberration 
Chinese hamster ovary cells 0, 50 - 250 µg/ml  Negative(a)  (Ivett et al., 1989) d,l-Menthol was used. The compound was tested up to toxic or nearly toxic 
concentration levels. The study is considered valid. 
 Chromosome 
aberration 
Human lymphocytes 0, 0.1, 1, 10 mM (1563 µg/ml4)  Negative(a)  (Murthy et al., 1991) The study is considered valid. 
 Gene mutation 
assay 
Mouse lymphoma L5178Y 
TK+/-cells 
0, 12.5 - 200 µg/ml  Negative(a) (Myhr and Caspary, 1991) d,l-Menthol was used. The maximum concentration was selected by a preliminary 
test The study is considered valid. 
NR = Not Reported 
(a)With and without metabolic activation. 
(b)With metabolic activation.  
(c) Without metabolic activation.  
(d) With and without pre-treatment with mitomycin C at 0.15 µM for 21 h.  
(e)With and without presence of beta-glucuronidase 
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Table 5:  Genotoxicity Data (in vivo) for 18Rev2 (EFSA, 2011). Substances listed in brackets are JECFA-evaluated substances 
Chemical Name [FL-no]  Test System Test Object  Route Dose Result  Reference  Comments 
2-Methylpropan-2-ol [02.052] In vivo 
Chromosomal 
Aberration assay 
Male rats Once via 
gavage 
0.2 × LD50 
 
Positive1 (Barilyak and 
Kozachuk, 1988) 
Validity questionable. This study was not in compliance with GLP and not in accordance 
with OECD guideline No. 475 (1983). Some main details of method and results are not 
available. 
The authors report the results of tests on a series of monohydric alcohols (from C1 to C16, 
18 compounds) in rat bone marrow cytogenetic tests. All compounds were claimed positive 
compared to the untreated control group, even though no statistics is shown. It is noted that 
a single control group, with 0.0% of cells with aberrations was used throughout the study. 
Lacking historical control data, it is not possible to establish whether the alleged positive 
results were due to and uniformly positive response elicited by all chemicals, or rather by 
an incidental very low frequency of aberrations in the group of rats (8 animals) used as 
control. In this respect, it is noted that the incidence of chromosomal aberrations observed 
with some ‘positive’ compounds, including 2-methylpropan-2-ol (1.6+/-0.5%), are close to 
background incidences commonly observed. Even the lack of a concurrent raise in gaps in 
treated animals casts doubts on an induced genotoxic effect. Moreover, the lack of a 
positive control group in the study is noted. For these reasons, the results of this study are 
considered inconclusive. 
 In vivo 
Micronucleus 
assay 
Mouse bone marrow 
erythrocytes 
i.p. × 3  
at 24 h 
intervals 
(=72 h)  
312.5, 625, and 1250 
mg/kg bw 
Negativ
e 
(NTP, 1996) This study is considered valid. It was not in compliance with GLP but in accordance with 
OECD guideline No. 474 (1983/1997) except that only 5 male animals were tested. The 
study is published in the Web and the report contains sufficient details. Due to the lack of 
an effect on the PCE/NCE ratio, it is unclear whether the test substance has reached the 
bone marrow. Relevance of the result is limited. 
 In vivo 
micronucleus 
assay 
Rat bone marrow 
cells 
i.p. × 3  
at 24 h 
intervals 
(=72 h) 
0, 39–1250 mg/kg 
bw,  
Negativ
e 
(NTP, 1997)  
 In vivo 
micronucleus 
assay 
Mouse peripheral 
blood cells 
Drinking 
water 
3000–40000 Negativ
e 
(NTP, 1995)  
2-Methylbut-3-en-2-ol [02.123] In vivo 
Micronucleus 
assay 
Mouse bone marrow 
erythrocytes 
Once via 
gavage 
500, 1000, 1500 
mg/kg 
Negativ
e 
(BASF, 1992) Summary in IUCLID data set only. According to this summary, the assay was performed in 
compliance with GLP and in accordance with OECD guideline 474. One thousand PCEs 
were counted per animal. The unpublished study report is not available for re-evaluation. 
(Linalool [02.013]) In vivo 
Micronucleus 
assay 
Mouse bone marrow 
erythrocytes 
Once via 
gavage 
1500 mg/kg Negativ
e 
(Meerts and van de 
Waart, 2001) 
This study is considered valid. It was in compliance with GLP and in accordance with 
OECD Guideline 474 (1997). However, due to the lack of an effect on the PCE/NCE ratio 
it is unclear whether the test substance reached the bone marrow. Thus, the relevance of the 
result is limited. 
(Myrcene [01.008]) In vivo 
micronucleus 
assay 
Rat bone marrow 
cells 
Gavage 0, 100, 500 or 1000 
mg/kg bw 
Negativ
e 
(Zamith et al., 1993)  
 In vivo 
micronucleus 
assay 
Mouse peripheral 
blood cells 
Gavage Up to 2000 mg/kg 
bw/day for 13 weeks 
Negativ
e 
(NTP, 2001)  
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Table 5:  Genotoxicity Data (in vivo) for 18Rev2 (EFSA, 2011). Substances listed in brackets are JECFA-evaluated substances 
Chemical Name [FL-no]  Test System Test Object  Route Dose Result  Reference  Comments 
(Menthol [02.015]) Host-mediated 
mutation assay 
S. Typhimurium  
TA1530 and G46; S. 
cerevisiae D3 
inoculated in mice 
(7–9 animals/group) 
Gavage  0, 1.45 - 5000 mg/kg 
bw (single dose) 
0, 1150 mg/kg 
bw/day (repeated 
doses) 
Equivoc
al 
(Food and Drug 
Research Laboratories, 
Inc., 1975) 
Negative results, with exception of the combination S Typhimurium  
TA1530 – 5000 mg/kg bw and S. cerevisiae D3 – 1150 mg/kg bw/day. This study is 
considered valid, but the equivocal result might have low relevance as the effect was only 
observed at very high (lethal) dose levels. 
 In vivo 
cytogenetic assay 
Male rat bone 
marrow cells 
Gavage 0, 1.45–3000 mg/kg 
bw (single dose) 
0, 1150 mg/kg 
bw/day (repeated 
doses) 
Negativ
e 
(Food and Drug 
Research Laboratories, 
Inc., 1975) 
Oral DL50 was determined as 940 mg/kg bw. The study is considered valid but the negative 
result is of limited relevance, as no effect on mitotic index was observed. However, testing 
at higher dose levels may not have been possible, due to lethality. 
 In vivo 
micronucleus 
assay 
B6C3F1 male mouse 
bone marrow cells 
i.p. 0, 250–1000 mg/kg 
bw/day, during 3 
days 
Negativ
e 
(Shelby et al., 1993) d,l-Menthol was used. The study is considered valid, but the negative result is of limited 
relevance, as no toxicity to the bone marrow was observed. However, testing at higher dose 
levels was not possible, because the highest dose caused 50% lethality. 
 In vivo dominant 
lethal assay 
Male rat fertility, 
spermatozoa 
Gavage 0, 1.45–3000 mg/kg 
bw (single dose) 
0, 1150 mg/kg 
bw/day (repeated 
doses) 
Negativ
e 
(Food and Drug 
Research Laboratories, 
Inc., 1975) 
This study is considered valid. 
 
Table 6:  Subchronic and chronic toxicity studies on [FL-no: 13.097] (substance evaluated in FGE.75Rev1) 
Chemical Name [FL-no]  Species; Sex 
No./Group 
Route  Dose levels Duration 
(days)  
NOAEL 
(mg/kg bw/day) 
Reference Comments 
Anhydrolinalool oxide (5) [13.097] Rat;  
M/F 
6 
Diet 0, 362.1, 633.4 
and 1189 mg/kg 
bw/day for males 
and 0, 385.5, 
661.9 and 921.2 
mg/kg bw/day 
for females 
14 385.5 (Bauter, 2012)  
 Rat; 
M/F 
20 
Diet 0, 46.4, 233.4 
and 452.9, 500 
mg/kg bw for 
males and 0, 
53.2, 257.3 and 
506.5 mg/kg bw 
for females 
90 105 (Bauter, 2013) OECD (408) compliant 90-day study. 
6-Acetoxydihydrotheaspirane [13.087] Rat; 
M/F 
Oral 
gavage 
3.0 mg/kg bw 
per day 
90 No NOAEL (Griffith, 1979) Study of limited value because parameters are missing 
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Summary of Safety Evaluation 
Table 7:  Summary of Safety Evaluation of Aliphatic, Acyclic and Alicyclic Terpenoid Tertiary Alcohols and Structurally Related Substances (JECFA, 
2008a) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI (a)  
US MSDI (g / capita 
per day) 
 
Class (b) 
Evaluation procedure 
path (c) 
Outcome on the 
named compound  
[(d) or (e)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
 
EFSA conclusion on the 
material of commerce 
02.018 
1646 
Nerolidol OH 43 
23 
Class I 
A3: Intake below threshold 
(d) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
02.245 
1643 
2,3,4-Trimethyl-3-pentanol 
OH  
0.49 
ND 
Class I 
A3: Intake below threshold 
(d) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
02.250 
1644 
2,4,8-Trimethyl-7-nonen-2-ol OH
 
3.0 
0.1 
Class I 
A3: Intake below threshold 
(d) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
02.251 
1645 
2,4,8-Trimethyl-3,7-nonadien-2-ol OH
 
3.0 
1 
Class I 
A3: Intake below threshold 
(d) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
Composition of 
stereoisomeric mixture to 
be specified. 
 
13.076 
1648 
6-Hydroxydihydrotheaspirane 
O
OH
0.12 
0.05 
Class II 
A3: Intake below threshold 
(d) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach (Step B4). 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.087 
1647 
6-Acetoxydihydrotheaspirane 
O
O
O
0.12 
ND 
Class II 
A3: Intake below threshold 
(d) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach (Step B4). 
According to EFFA, the 
commercial product is a 
mixture of two isomers; 
identity of the isomers to be 
specified. 
(a) EU MSDI: Amount added to food as flavour in (kg/year) × 10E9 / (0.1 × population in Europe (= 375 × 10E6) × 0.6 × 365)  =  µg / capita per day. 
(b) Thresholds of concern: Class I = 1800 µg/ person per day, Class II = 540 µg / person per day, Class III = 90 µg/person per day. 
(c) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
(d) No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e) Data must be available on the substance or closely related substances to perform a safety evaluation. 
ND: not determined 
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Table 8:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (EFSA FGE.18Rev2 and EFSA FGE.75 
Rev1) (EFSA, 2011 and EFSA, 2009) 
FL-no EU Register name Structural formula MSDI (a) 
(g/capita per 
day) 
Class (b) 
Evaluation procedure path 
(c) 
Outcome on the named 
compound  
[(d) or (e)] 
Outcome on the 
material of 
commerce [(f), (g) 
or (h)] 
Evaluation remarks 
02.054 
 
p-Menthane-1,8-diol 
OH
OH
 
11 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.140 
 
1,2-Dihydrolinalool OH
 
0.044 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.149 
 
Elemol 
HO
1.6 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.168 
 
Isophytol 
OH
0.037 
 
Class I 
A3: Intake below threshold 
4) 7)  
02.171 
 
p-Menthan-8-ol 
OH
 
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.206 
 
Sclareol 
H
OH
OHS
S
R
R
R
0.67 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.219 
 
2,6-Dimethyl-2-heptanol 
OH
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 8:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (EFSA FGE.18Rev2 and EFSA FGE.75 
Rev1) (EFSA, 2011 and EFSA, 2009) 
FL-no EU Register name Structural formula MSDI (a) 
(g/capita per 
day) 
Class (b) 
Evaluation procedure path 
(c) 
Outcome on the named 
compound  
[(d) or (e)] 
Outcome on the 
material of 
commerce [(f), (g) 
or (h)] 
Evaluation remarks 
02.226 
 
[S-(cis)]-3,7,11-Trimethyl-1,6,10-
dodecatrien-3-ol 
OH 0.049 
 
Class I 
A3: Intake below threshold 
4) 8)  
02.230 
 
Terpineol 
OH
alfa Terpineol shown
1200 
 
Class I 
A3: Intake below threshold 
4) 7) a) 
02.253 
1850 
2,4-Dimethyl-4-Nonanol OH 0.24 
 
Class I 
A3: Intake below threshold 
4) 7)  
09.614 
 
Linalyl valerate O
O
0.43 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.617 
 
p-Menthan-8-yl acetate 
O
O
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.671 
 
Nerolidyl acetate 
OO
0.061 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.120 
 
Cedrol 
OH
H
13 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
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Table 8:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (EFSA FGE.18Rev2 and EFSA FGE.75 
Rev1) (EFSA, 2011 and EFSA, 2009) 
FL-no EU Register name Structural formula MSDI (a) 
(g/capita per 
day) 
Class (b) 
Evaluation procedure path 
(c) 
Outcome on the named 
compound  
[(d) or (e)] 
Outcome on the 
material of 
commerce [(f), (g) 
or (h)] 
Evaluation remarks 
02.144 
 
2,6-Dimethyloct-7-en-2-ol OH
 
0.0012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
02.185 
 
Myrcenol 
OH
 
0.012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
02.191 
 
Ocimenol 
OH
 
0.012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
09.171 
 
Cedryl acetate 
O
H
O
0.99 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
09.669 
 
Myrcenyl acetate 
O
O
8.6 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
09.808 
 
Guaiyl acetate 
O
O
0.0012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
02.041 
 
2-Methylbutan-2-ol 
OH
2.7 
 
Class II 
A3: Intake below threshold 
(d) (f)  
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Table 8:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (EFSA FGE.18Rev2 and EFSA FGE.75 
Rev1) (EFSA, 2011 and EFSA, 2009) 
FL-no EU Register name Structural formula MSDI (a) 
(g/capita per 
day) 
Class (b) 
Evaluation procedure path 
(c) 
Outcome on the named 
compound  
[(d) or (e)] 
Outcome on the 
material of 
commerce [(f), (g) 
or (h)] 
Evaluation remarks 
02.052 
 
2-Methylpropan-2-ol OH
 
0.012 
 
Class II 
A3: Intake below threshold 
(d) (f)  
02.123 
 
2-Methylbut-3-en-2-ol 
OH
0.0012 
 
Class II 
A3: Intake below threshold 
(d) (f)  
02.147 
 
3,6-Dimethyloctan-3-ol OH 0.0012 
 
Class II 
A3: Intake below threshold 
(d) (g)  
02.150 
 
Geranyl linalool 
HO
0.026 
 
Class II 
A3: Intake below threshold 
(d) (f)  
02.181 
 
2-Methylpentan-2-ol OH 0.12 
 
Class II 
A3: Intake below threshold 
(d) (f)  
02.184 
 
3-Methylpentan-3-ol OH 0.0012 
 
Class II 
A3: Intake below threshold 
(d) (f)  
02.203 
 
2-Phenylpropan-2-ol 
OH
 
0.0012 
 
Class II 
A3: Intake below threshold 
(d) (f)  
09.356 
 
1,1-Dimethylethyl propionate 
O
O 0.0012 
 
Class II 
A3: Intake below threshold 
(d) (f)  
02.197 
 
1,2,3,4,4a,5,6,7-Octahydro-2,5,5-
trimethylnaphthalen-2-ol 
OH 0.026 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
(a) EU MSDI: Amount added to food as flavour in (kg/year) × 10E9 / (0.1 × population in Europe (= 375 × 10E6) × 0.6 × 365)  =  µg / capita per day 
(b) Thresholds of concern: Class I = 1800, Class II = 540, Class III = 90 µg / capita per day 
(c) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
(d) No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e) Data must be available on the substance or closely related substances to perform a safety evaluation. 
(f) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach) 
(g) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
(h) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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DOCUMENTATION PROVIDED TO EFSA 
1. Bauter MR, 2012. Anhydrolinalool oxide: palatability/toxicity study: a 14-day dietary study in 
rats. Product Safety Labs. Study no. 33068. February 8, 2012. Unpublished report submitted 
by EFFA to FLAVIS Secretariat 
2. Bauter MR, 2013b. Anhydrolinalool oxide: a 90-day dietary study in rats. Product Safety 
Labs. Study no. 33452. January 14, 2013. Unpublished report submitted by EFFA to FLAVIS 
Secretariat. 
3. Bertens AMC and van de Waart EJ, 2000. Evaluation of the ability of linalylacetate to induce 
chromosome aberrations in cultured peripheral human lymphocytes. Hoffmann-LaRoche. 
Report no. 38576, study no. 289968. June 22, 2000. Unpublished report submitted by EFFA 
to FLAVIS Secretariat. 
4. EFFA, 2006. Addendum of 7 flavouring substances (candidate chemicals) to the flavouring 
group evaluation of the chemical group 06 (Annex I of 1565/2000/EC) structurally related to 
aliphatic, alicyclic and alicyclic terpenoid tertiary alcohols and structurally related substances 
used as flavouring substances. November 2006. Addendum to FGE.18 (EFFA submission 
2003-1). Unpublished data submitted by EFFA to FLAVIS Secretariat. Flavis/8.64. 
5. EFFA, 2007. E-mail from Jan Demyttenaere, EFFA to FLAVIS Secretariat, National Food 
Institute, Technical University of Denmark. Dated 8 February 2007. RE: FLAVIS submissions 
- use levels for Category 14.2 - Alcoholic beverages. FLAVIS/8.70. 
6. EFFA, 2010. EFFA Letters to EFSA for clarification of specifications and isomerism for 
which data were requested in published FGEs. 
7. Food and Drug Research Laboratories, Inc., 1975. Mutagenic evaluation of compound FDA 
71-57, menthol. Litton Bionetics, Inc. Weir, R.J. January 14, 1975. Unpublished report 
submitted by EFFA to FLAVIS Secretariat. 
8. Griffiths PJ, 1979. Report on acute oral toxicity (LD/50) and three-month oral toxicity (91 
days) of TT 182. Unpublished report to the Flavor and Extract Manufacturers Association, 
Washington, DC, USA. Submitted to WHO by the Flavor Manufacturers Association of the 
United States, Washington, DC, USA. 
9. Haworth SR, Lawlor TE, Williams NA, Burke PJ, Hans LJ, Reichard GL, Wagner VO and 
Olewine SM, 1981a. Salmonella/mammalian-microsome preincubation mutagenicity assay 
using Arconol with cover letter dated 03/24/94. EPA Doc 86940000260, microfiche no. 
OTS0572363. Date 05/08/81. Unpublished data submitted by EFFA to FLAVIS Secretariat. 
10. Haworth SR, Lawlor TE, Smith JK, Williams NA, Burke PJ, Reichard GL, Hans LJ, Olewine 
SM and Wagner VO, 1981b. Salmonella/mammalianmicrosome preincubation mutagenicity 
assay with t-butyl alcohol with cover letter dated 03/24/94. EPA Doc 86940000253, 
microfiche no. OTS0572356. Date 05/08/81. Unpublished data submitted by EFFA to 
FLAVIS Secretariat 
11. Kirby PE, Pizzarello RF, Williams PE, Wattam RE, Clarke JJ, Condon MB, Johnson JL, 
Maddenm G, Hoynak GJ, Stroud RM and Reichard GL, 1981. Evaluation of test article t-butyl 
alcohol 99.9% (MRI #635) & arconol (MRI #636) for mutagenic potential employing the 
L5178Y TK+/- mutagenesis assay w/cover letter dated 03/24/94. Arco Chemical Co. EPA 
Doc 6940000262, microfiche no. OTS0572365. Date 08/06/81. Unpublished data submitted 
by EFFA to FLAVIS Secretariat. 
12. Kirby PE, Duglas-Tabor Y, Simmons RT, Voglezon RA, Rogers-Back AM, Brauninger RM, 
O’Keefe TR and Fernandez-Madrid AM, 1984. Mouse lymphoma mutagenesis assay with 
#70437 (alpha-terpineol). Short-term test program sponsored by The Division of Cancer 
Etiology, National Cancer Institute. Study no. ML-NCI#109. Unpublished data submitted by 
EFFA to FLAVIS Secretariat. 
Flavouring Group Evaluation 90, Revision 1
 
EFSA Journal 2016;14(1):4336 32
13. Lorillard (Lorillard Tobacco Company), 1982. Mutagenicity evaluation of alpha-terpineol in 
the mouse lymphoma mutation assay. LBI Project no. 20989. Unpublished report submitted 
by EFFA to FLAVIS Secretariat. 
14. Lorillard (Lorillard Tobacco Company), 1983. Mutagenicity evaluation of alpha-terpineol in 
the Ames Salmonella/microsome plate test. Lorillard Research Center. LBI Project no. 20988. 
Unpublished report submitted by EFFA to FLAVIS Secretariat. 
15. Meerts IATM and van de Waart EJ, 2001. Micronucleus test in bone marrow cells of the 
mouse with linalool. Hoffman-LaRoche. Report no. 38577, project no. 328826. Date 18 
October, 2001. Unpublished report submitted by EFFA to FLAVIS Secretariat. 
16. National Cancer Institute, 1983. Mutagenicity of G70437. alpha-Terpineol. Unpublished data 
submitted by EFFA to FLAVIS Secretariat. 
17. Putman DL, 1985. An in vitro evaluation of t-butyl alcohol 99.9% to produce sister chromatid 
exchanges in Chinese hamster ovary cells with cover letter dated 03/24/94. Arco Chemical Co. 
EPA Doc 86940000254, microfiche no. OTS0572357. Date 06/05/81. Unpublished data 
submitted by EFFA to FLAVIS Secretariat. 
18. Thilagar A, Kumaroo PV, McCoy S and Reichard G, 1981. An in vitro evaluation of t-butyl 
alcohol - Arconol Batch # A209411 to produce sister chromatid exchanges in Chinese hamster 
ovary cells  with cover letter dated 03/24/94. Arco Chemical Co. EPA Doc 86940000261, 
microfiche no. OTS0572364. Date 06/05/81. Unpublished data submitted by EFFA to 
FLAVIS Secretariat. 
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ABBREVIATIONS 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  deoxyribonucleic acid 
EPA  United States Environmental Protection Agency  
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  good laboratory practise 
i.p.  intraperitoneal 
IR  infrared spectroscopy 
JECFA  Joint FAO/WHO Expert Committee on Food Additives 
MSDI  maximised survey-derived daily intake 
mTAMDI modified theoretical added maximum daily intake 
NOAEL no observed adverse effect level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
PCE  polychromatic erythrocyte 
SCE  sister chromatic exchange 
SCF  Scientific Committee on Food 
WHO  World Health Organization 
